Copley Acquisition to Combine with Ignite Proteomics in $150M Merger
COPL•Copley Acquisition Corp will merge with Ignite Proteomics under a SPAC structure valuing Ignite at $150 million on a $10-per-share reference price. The transaction includes up to $20 million of SPAC financing and $10 million of incremental fundraising, with expected closing by September 30.
1. Deal Terms and Valuation
Copley Acquisition Corp has entered into a merger agreement to combine with Ignite Proteomics under a SPAC structure. The deal values Ignite at $150 million based on a $10 per share reference price and positions the combined entity for an NYSE listing.
2. Financing Structure and Timeline
The SPAC sponsor will seek up to $20 million in transaction financing while Ignite aims to raise $10 million through equity, debt, or backstop arrangements. The transaction is scheduled to close by September 30, with potential extensions if agreed by both parties.
3. Governance of Combined Entity
Post-closing, the board is expected to comprise seven directors, with at least four meeting NYSE independence requirements. Ignite’s current management team will lead the combined holding company, which must deliver audited financial statements within 10 business days of signing.
4. Strategic Outlook for Ignite
Proceeds from the transaction will support Ignite’s commercialization efforts, clinical evidence generation, and working capital needs. The company plans to expand its cancer-testing platform beyond breast cancer to additional tumor types over time.
